Education
About Us
Working with TipRanks
Follow Us
Immunotech Biopharm Ltd (HK:6978)
:6978
Total Valuation
Immunotech Biopharm Ltd has a market cap or net worth of HK$1.75B. The enterprise value is HK$1.91B.
Market CapHK$1.75B
Enterprise ValueHK$1.91B
Share Statistics
Immunotech Biopharm Ltd has 617,500,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding617,500,800
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Immunotech Biopharm Ltd’s return on equity (ROE) is 14.06 and return on invested capital (ROIC) is -46.52%.
Return on Equity (ROE)14.06
Return on Assets (ROA)-0.33
Return on Invested Capital (ROIC)-46.52%
Return on Capital Employed (ROCE)-1.49
Revenue Per Employee0.00
Profits Per Employee-1.21M
Employee Count154
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Immunotech Biopharm Ltd is ―. Immunotech Biopharm Ltd’s PEG ratio is 0.13.
PE Ratio―
PS Ratio0.00
PB Ratio-83.60
Price to Fair Value-83.60
Price to FCF-7.23
Price to Operating Cash Flow-33.43K
PEG Ratio0.13
Income Statement
In the last 12 months, Immunotech Biopharm Ltd had revenue of 0.00 and earned -186.91M in profits. Earnings per share was -0.36.
Revenue0.00
Gross Profit0.00
Operating Income-198.78M
Pretax Income-186.42M
Net Income-186.91M
EBITDA-148.68M
Earnings Per Share (EPS)-0.36
Cash Flow
In the last 12 months, operating cash flow was -46.23K and capital expenditures -7.61K, giving a free cash flow of -53.83K billion.
Operating Cash Flow-46.23K
Free Cash Flow-53.83K
Free Cash Flow per Share>-0.01
Dividends & Yields
Immunotech Biopharm Ltd pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.33
52-Week Price Change30.14%
50-Day Moving Average3.38
200-Day Moving Average3.63
Relative Strength Index (RSI)38.65
Average Volume (3m)1.34M
Important Dates
Immunotech Biopharm Ltd upcoming earnings date is Mar 20, 2026, TBA (Confirmed).
Last Earnings DateAug 20, 2025
Next Earnings DateMar 20, 2026
Ex-Dividend Date―
Financial Position
Immunotech Biopharm Ltd as a current ratio of 0.20, with Debt / Equity ratio of -78.46%
Current Ratio0.20
Quick Ratio0.19
Debt to Market Cap0.24
Net Debt to EBITDA-0.47
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Immunotech Biopharm Ltd has paid 926.00K in taxes.
Income Tax926.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Immunotech Biopharm Ltd EV to EBITDA ratio is -7.94, with an EV/FCF ratio of -7.68.
EV to Sales0.00
EV to EBITDA-7.94
EV to Free Cash Flow-7.68
EV to Operating Cash Flow-9.39
Balance Sheet
Immunotech Biopharm Ltd has HK$21.05M in cash and marketable securities with HK$111.73M in debt, giving a net cash position of -HK$90.68M billion.
Cash & Marketable SecuritiesHK$21.05M
Total DebtHK$111.73M
Net Cash-HK$90.68M
Net Cash Per Share-HK$0.15
Tangible Book Value Per Share-HK$0.07
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Immunotech Biopharm Ltd is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast27.90%